<DOC>
	<DOCNO>NCT00099320</DOCNO>
	<brief_summary>This study design compare effect twice-daily exenatide plus oral antidiabetic ( OAD ) agents twice-daily placebo plus OAD respect glycemic control , measure hemoglobin A1c ( HbA1c ) , patient type 2 diabetes experience inadequate glycemic control OAD alone .</brief_summary>
	<brief_title>Safety Efficacy Exenatide Patients With Type 2 Diabetes Using Thiazolidinediones Thiazolidinediones Metformin</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<mesh_term>2,4-thiazolidinedione</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Treated thiazolidinedione ( TZD ) alone combination metformin . TZD dose stable least 120 day prior screen , patient metformin must stable dose least 30 day prior screen . HbA1c 7.1 % 10.0 % , inclusive . Body mass index ( BMI ) 25 kg/m^2 45 kg/m^2 . Patient previously study use exenatide GLP1 analog . Treated oral antidiabetic medication TZD metformin within 3 month screen . Treated oral insulin within 3 month screen .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>exenatide</keyword>
	<keyword>exendin-4</keyword>
	<keyword>diabetes</keyword>
	<keyword>Amylin</keyword>
	<keyword>Lilly</keyword>
</DOC>